Tests a Chinese herbal formula alongside standard care for chronic kidney disease
Tests a Chinese herbal formula added to standard care in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Effect of Chinese Herbal Medicine on Kidney Function in Non-Diabetic CKD
Key facts
- Where
- Yunlin, TaiwanSee the site
Where in Taiwan
- China Medical University Beigang HospitalYunlin, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China Medical University Hospital
- Trial code
- NCT07657338
- Record updated
- 18 June 2026
- Original description
This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (CKD-1) as an add-on therapy to standard treatment in patients with stage 3-4 non-diabetic chronic kidney disease. Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with CKD-1 for 12 weeks. Kidney function, urine protein levels, and quality of life will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether CKD-1 can improve renal function and quality of life in this patient population.Read full original descriptionShow less
Effects of Chinese Herbal Medicine as an Adjunctive Therapy on Renal Function in Patients With Non-Diabetic Chronic Kidney Disease: A Pilot Randomized Controlled Trial
This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (CKD-1) as an add-on therapy to standard treatment in patients with stage 3-4 non-diabetic chronic kidney disease. Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with CKD-1 for 12 weeks. Kidney function, urine protein levels, and quality of life will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether CKD-1 can improve renal function and quality of life in this patient population.
Inclusion: Adults aged ≥18 years; Patients diagnosed with stage 3-4 chronic kidney disease (CKD), confirmed by a nephrologist and classified as ICD-10-CM codes N18.3-N18.4; Ability to understand the study procedures and provide written informed consent; Willingness to comply with study procedures and follow-up visits.
Exclusion: Acute kidney injury or major kidney-related surgery within 3 months prior to enrollment; Malignancy currently receiving chemotherapy, radiotherapy, or other systemic anticancer treatment; History of diabetes mellitus; End-stage disease defined under palliative care regulations; Known allergy to any components of the CKD-1 herbal formula, including Astragalus membranaceus, Salvia miltiorrhiza, Poria cocos, Moutan cortex, Scutellaria baicalensis, Lonicera japonica, or Alisma orientale; Alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal; Participation in another clinical trial within 3 months that may affect renal function; Pregnancy or breastfeeding.